RudaCure Inc., a venture company specializing in the desarrollo of tratamientos for trastornos sensoriales, anunció el 30th that its self-developed tratamiento de la enfermedad de ojo seco candidato substance RCI001 ha sido reconocida por its comercialización potential and ha sido seleccionada para the Ministry of Trade, Industry and Energy's 'I+D Rediscovery Project,' the Ministry of SMEs and Startups' '2020 BIG3 Sector SME Innovación Growth Support Project,' and Incheon Technopark's 'Startup Park Project,' thereby laying the foundation for ensayo clínicos.
https://www.donga.com/news/It/article/all/20200729/102213491/2